布罗鲁单抗治疗新生血管性年龄相关性黄斑变性的早期经验
这项回顾性病例系列研究纳入美国15家中心172只眼,评估玻璃体腔注射布罗鲁单抗6 mg治疗nAMD的早期结局。结果显示视力保持稳定,黄斑中心凹厚度平均下降26.9 μm,眼内炎症发生率为8.1%,其中1只眼出现闭塞性视网膜血管炎伴严重视力丧失。
要点
- 布罗鲁单抗治疗后平均视力保持稳定,黄斑中心凹厚度显著下降。
- 眼内炎症发生率为8.1%,多数自限,但1只眼出现闭塞性视网膜血管炎。
- 多数眼为非初治眼,因持续积液从既往抗VEGF药物转换。
核心结论
- 布罗鲁单抗玻璃体腔注射治疗nAMD后视力保持稳定,黄斑中心凹厚度降低。
- 眼内炎症事件从轻微自限到1只眼出现严重闭塞性视网膜血管炎。
研究设计与样本
- 回顾性病例系列研究,纳入美国15家私立或学术眼科中心连续患者。
- 共172只眼来自152例患者,平均年龄80.0岁,87例女性(57.2%)。
- 研究期间为2019年10月17日至2020年4月1日,由6名视网膜专家治疗。
主要发现
- 14只眼(8.1%)报告眼内炎症,其中6只眼自限且未经治疗缓解。
- 1只眼(0.6%)出现闭塞性视网膜血管炎和严重视力丧失。
关键数值与推荐
- 研究眼平均接受1.46次布罗鲁单抗玻璃体腔注射(标准差0.62)。
- 166只眼(96.5%)为非初治眼,其中109只眼(65.7%)因OCT持续积液从既往抗VEGF药物转换。
临床怎么用
- 布罗鲁单抗可用于nAMD治疗,但需警惕眼内炎症,包括罕见的闭塞性视网膜血管炎。
- 治疗后黄斑中心凹厚度可下降,视力保持稳定。
局限性
- 回顾性设计,样本来自15家中心,随访时间有限。
- 多数眼为非初治眼,结果可能受既往治疗影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report clinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020. EXPOSURES: Treatment with brolucizumab IVI, 6 mg. MAIN OUTCOMES AND MEASURES: Change in mean visual acuity (VA) and optical coherence tomography parameters, including mean central subfield thickness and presence or absence of subretinal and/or intraretinal fluid. Secondary outcomes included ocular and systemic safety. RESULTS: A total of 172 eyes from 152 patients (87 women [57.2%]; mean [SD] age, 80.0 [8.0] years) were included. Most eyes (166 [96.5%]) were not treatment naive, and 65.7% of these eyes (109 of 166) were switched from the prior anti-VEGF agent because of persistent fluid detected on optical coherence tomography scans. Study eyes received a mean (SD) of 1.46 (0.62) brolucizumab IVIs. The mean (SD) VA prior to starting brolucizumab was a 64.1 (15.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (Snellen equivalent, 20/50) and was a 63.3 (17.2) ETDRS letter score (Snellen equivalent, 20/63) at the last study evaluation (mean difference, 0.8; 95% CI, -2.7 to 4.3; P = .65). When analyzed by number of brolucizumab IVIs, the presence or absence of fluid prior to starting brolucizumab, or the presence or absence of intraocular inflammation after receiving brolucizumab, there was no difference in mean VA prior to starting brolucizumab compared with after brolucizumab IVIs or at the final study evaluation. The mean (SD) central subfield thickness in all eyes prior to starting brolucizumab was 296.7 (88.0) μm and was 269.8 (66.5) μm at the last study examination (mean difference, 26.9 µm; 95% CI, 9.0-44.7 µm; P = .003). Intraocular inflammation was reported in 14 eyes (8.1%) and was self-limited and resolved without treatment in almost half those eyes (n = 6). One previously reported eye (0.6%) had occlusive retinal vasculitis and severe loss of vision. CONCLUSIONS AND RELEVANCE: In this analysis of brolucizumab IVI for nAMD, VA remained stable, with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild with spontaneous resolution to severe occlusive retinal vasculitis in 1 eye.
引用
- Enríquez AB, Baumal CR, Crane AM, et al. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021. PMID: 33630045. doi:10.1001/jamaophthalmol.2020.7085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。